Lastly, for lung cancer patients that develop metastases to the central nervous system (CNS), detection of EGFR mutations in the cerebrospinal fluid (CSF) has been proven to be more efficient than plasma to evaluate PFS [50]. The gene discussed is EGFR; the disease is lung carcinoma.